MedBulletinsAura Celeste
Vascular

Monthly vascular bulletin — November 19, 2026

🎧 Listen to this issueAudio newscast · 6:11 min

Colleagues: this issue covers October 31 through November 19, 2026, the stretch since the special edition on inferior vena cava filters, and also includes two late-October developments that the special edition did not cover: a trial published on October 26 and an FDA clearance dated October 28 and announced on November 4. The period was dominated by U.S. regulatory decisions and industry moves (carotid, intravascular imaging, hemodialysis access) and by publications from Japan and Korea in peripheral arterial disease. There were no large new randomized trials in peripheral arterial or venous disease within the period; what we have is one multicenter series, one meta-analysis, and a small single-center trial. Eight verified items, two of them from outside North America and Western Europe.

Peripheral arterial disease, calcium, and plaque modification

1. Jetstream atherectomy in calcified femoropopliteal disease: proximal protection is associated with less distal embolization

[Publication] [Japan]
A Japanese multicenter retrospective series (Tsujimura, Iida, and colleagues) published online November 14, 2026, in Cardiovascular Intervention and Therapeutics: 147 limbs in 126 patients with calcified femoropopliteal lesions treated with Jetstream atherectomy plus drug-coated balloon. Overall distal embolization was 21.1%: 28.0% with no protection (n = 25), 30.2% with a distal filter alone (n = 63), 13.5% with filter plus proximal protection (n = 37), and 0% with the flow-controlled anti-embolic technique (n = 22; p = 0.012). On multivariable analysis, chronic limb-threatening ischemia was associated with more embolization (adjusted OR 2.68; 95% CI 1.10–6.54) and proximal protection, including the flow-controlled technique, with less (adjusted OR 0.26; 95% CI 0.07–0.96); at six months outcomes were comparable among groups and there were no major amputations.
Why it matters: it suggests that a distal filter alone is not enough in heavy calcium and that controlling antegrade flow may make the difference; but the study is retrospective, the flow-controlled group is small, and the authors themselves say the finding for that technique should be considered "exploratory and hypothesis-generating."

Sources

  • [Article] Tsujimura T, Yoshii D, Hata Y, et al. "Association between embolic protection strategy and distal embolization during Jetstream atherectomy for calcified femoropopliteal lesions." Cardiovasc Interv Ther. 2026. DOI: 10.1007/s12928-026-01369-w. Subscription (free abstract). https://link.springer.com/article/10.1007/s12928-026-01369-w

2. FDA clears Evident Vascular's AI-powered intravascular ultrasound platform

[FDA regulatory] [USA]
The FDA cleared through the 510(k) pathway (K261648, letter dated October 28, 2026) the Evident Vascular Guidance System and Evident Vascular's peripheral imaging catheters, indicated for ultrasound examination of intravascular pathology; the catheters are for peripheral vascular pathology only. The company announced the clearance on November 4. According to the coverage, the platform combines a broad frequency bandwidth, dynamic frequency control, AI-based processing, and voice control, and the company plans to expand its AI features as clinical data accumulate.
Why it matters: it adds another peripheral IVUS option, but the clearance is by substantial equivalence to a device already on the market, the FDA summary states that no clinical performance testing was conducted, and the only endorsement cited in the coverage is the opinion of one physician (Eric Secemsky, Beth Israel Deaconess Medical Center).

Sources

3. Ginkgo extract in claudication: Korean meta-analysis of 14 trials

[Meta-analysis] [Korea]
A team from Seoul St. Mary's Hospital (Catholic University of Korea; corresponding author Sun Cheol Park) published on November 4, 2026, in the Journal of Clinical Medicine, with Korean press coverage on November 19, a systematic review and meta-analysis of 14 randomized, double-blind, placebo-controlled trials (893 randomized participants) of Ginkgo biloba extract for intermittent claudication in peripheral arterial disease, adding the trials published after the 2013 Cochrane review, including a 2026 Korean trial. Maximal walking distance (absolute claudication distance), analyzed in 12 studies with 584 participants and standardized by energy expenditure, improved by 3.50 kcal versus placebo (95% CI 0.02–6.98; p = 0.049); in the seven 24-week trials, by 4.67 kcal (95% CI 2.26–7.08; p < 0.001), while the 12- to 16-week trials showed no significant difference. The approximate 60 m and 81 m equivalents given by the authors assume a 70 kg patient on a flat treadmill at 3.2 km/h. Adverse events were comparable to placebo.
Why it matters: the effect is small, overall significance is borderline, and heterogeneity is moderate (I² 57.2%), with differing formulations, doses, and durations; it does not change practice (supervised exercise, cilostazol where available, and risk-factor control still come first). The study was partially funded by SK Chemicals, and three of the five authors are employed by LSK Global Pharma Services.

Sources

Venous disease

4. Surgery versus ultrasound-guided foam for the anterior accessory saphenous vein: three-year randomized trial from Vienna

[Clinical trial] [Austria]
A single-center, investigator-initiated, unblinded randomized trial (Kienzl, Tzaneva, and colleagues; Medical University of Vienna) published October 26, 2026, in the Journal of Clinical Medicine: 39 limbs in 35 patients with isolated anterior accessory saphenous vein incompetence, 19 randomized to surgery (high ligation with phlebectomy) and 20 to ultrasound-guided polidocanol foam sclerotherapy (mean 20.3 mg per session; 50% closed after one session). Duplex recurrence in the anterior saphenous territory at three years, the primary endpoint: 33% with surgery vs 63% with foam (difference 30 points; 95% CI −2 to 54; p = 0.103; not significant). At one year the difference was significant (11% vs 65%; p < 0.001); neovascularization was higher after surgery (44% vs 5% at three years); clinical recurrence did not differ (39% vs 37%). There was no external funding.
Why it matters: it is one of the few randomized trials dedicated to the anterior accessory saphenous vein, but it enrolled in 2006–2008, was registered retrospectively (NCT02010723), has 39 limbs, did not prospectively collect quality-of-life or severity scores, and the mean vein diameter (about 9 mm) exceeds the usual threshold for foam; it is useful for context, not for choosing a technique.

Sources

  • [Article] Kienzl P, Lorenz H, Stolkovich S, et al. "Surgery Versus Ultrasound-Guided Foam Sclerotherapy for the Treatment of Isolated Anterior Saphenous Vein Incompetence: A Single-Center Randomized Trial." J Clin Med. 2026;15(21):8343. DOI: 10.3390/jcm15218343. Open access (CC BY 4.0). https://pmc.ncbi.nlm.nih.gov/articles/PMC13764045

Carotid, vascular access, and other

5. FDA approves the CGuard Prime stent for transcarotid artery revascularization (TCAR)

[FDA regulatory] [USA]
InspireMD announced on November 12, 2026, FDA approval of the PMA supplement extending the CGuard Prime (self-expanding nitinol stent covered with the MicroNet micromesh, 80 cm delivery system) to TCAR, used with an embolic protection system specified in the labeling, in patients at high risk for endarterectomy; the pivotal study used the ENROUTE neuroprotection system. It rests on CGUARDIANS II, a prospective, multicenter, single-arm pivotal study of 50 patients at 11 sites: 100% acute device success and, at 30 days, no deaths, strokes, myocardial infarctions, or stent thrombosis.
Why it matters: it gives InspireMD a route into TCAR, but 50 patients with no comparator and no one-year data is a minimal evidence base; the release also notes a voluntary U.S. recall of the 135 cm delivery system, and the company's own neuroprotection system (SwitchGuard) remains investigational.

Sources

6. Medtronic to acquire Contego Medical: TCAR with integrated embolic protection and peripheral thrombectomy

[Industry] [USA]
Medtronic announced on November 16, 2026 (from Galway, Ireland) an agreement to acquire Contego Medical for $380 million plus potential post-closing payments, with closing expected in its fiscal third quarter and still pending. The deal would add the Neuroguard IEP Direct System, recently FDA-approved and described by the company as the first and only TCAR system with integrated embolic protection that also uses flow reversal, and the Excipio thrombectomy devices, complementary to Medtronic's Liberant system. The release cites 30-day PERFORMANCE III results: no strokes, neurological deaths, cranial nerve injuries, or myocardial infarctions.
Why it matters: together with the CGuard Prime approval, it adds competition in TCAR, which could pressure pricing and accelerate comparative data; but the PERFORMANCE III figures come from a press release, with no sample size or peer-reviewed publication, and PERFORMANCE II is mentioned only in a footnote.

Sources

7. Humacyte files with the FDA to extend its acellular vessel to hemodialysis access

[Industry] [USA]
On November 19, 2026, Humacyte announced that it has submitted to the FDA a supplemental Biologics License Application (sBLA) to add arteriovenous access for hemodialysis in patients with end-stage kidney disease at increased risk of arteriovenous fistula maturation failure as an indication for its acellular tissue-engineered vessel (ATEV, marketed as Symvess for trauma); the filing rests on the interim analysis of the phase 3 V012 trial and on two earlier phase 3 trials (V006 and V007). According to the company, the FDA has 60 days to decide whether the application is acceptable for filing, and Humacyte has requested Priority Review. V012, a randomized, open-label trial, compares the ATEV with arteriovenous fistula in women needing hemodialysis access. On November 11 Humacyte announced a V012 presentation scheduled for November 18 at VEITH (New York); the cited interim results had already been announced on June 10, 2026: in the first 80 patients at 12 months, 220 catheter-free days with the ATEV versus 129 with fistula (p = 0.0007), 6 infections per 100 patient-years versus 23, and no spontaneous ruptures.
Why it matters: the "catheter-free days" endpoint is clinically meaningful and the population (women, with higher maturation failure) is well chosen, but a filing is not an approval and its acceptance for review has not yet been reported; the efficacy data come from an interim analysis of an open-label, manufacturer-sponsored trial without peer-reviewed publication, and Symvess already carries a boxed warning for graft failure (rupture or anastomotic failure with life-threatening hemorrhage) in its trauma indication.

Sources

8. Sirtex adds the Hourglass vascular plug for peripheral embolization

[Industry] [USA]
Sirtex Medical announced on November 16, 2026, the acquisition of the Hourglass embolization plug, FDA 510(k)-cleared since 2017 and indicated to obstruct or reduce flow in peripheral vessels 6 to 8 mm in diameter, joining its Lava liquid embolic. The device had a limited U.S. release and the company is preparing general availability.
Why it matters: it broadens the catheter-based occlusion toolkit (preoperative embolization, type II endoleaks, hypogastric arteries), but there are no new clinical data, only one user's opinion, and the clearance is nine years old.

Sources

Upcoming meetings and dates

VEITHsymposium 2026, 53rd edition, New York, November 17–21, 2026 (under way as this issue closes).
VII International Conference "Pokrovsky Readings" of the Russian Society of Angiologists and Vascular Surgeons, A. V. Vishnevsky National Medical Research Center of Surgery, Moscow, November 20–21, 2026. (Source in Russian)
https://angiolsurgery.org/events/2026/11/20-21/

Get every issue by email

Free. One email with each new issue, with a short summary and links to the page and the audio. No ads inside the content: any sponsor is identified and has no say in the selection. We do not share your data; unsubscribe with a single message.